FDA approval date
End of March, no year-over-year change applicable as this is the first approval.
Launch timeline
Launched a couple of weeks after FDA approval, no year-over-year change applicable as this is the first launch.
Q2 results
646 start forms and 295 prescribers in 3 months post-launch, no year-over-year comparison provided as this is the first launch.
SLNO
$49.25+Infinity%1D
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 49.500
Low
106.00
Averages
118.50
High
145.00
Current: 49.500
Low
106.00
Averages
118.50
High
145.00
Wolfe Research
Kalpit Patel
Outperform
initiated
$75
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
$75
2025-11-17
initiated
Outperform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. Shares have been weak following a slowing of new patient starts quarter-over-quarter, but the firm's survey results suggest that the safety concerns are "overblown" and the directional trend for utilization is favorable for the next one to two years, the analyst tells investors.
Wells Fargo
Derek Archila
Overweight
downgrade
$123 -> $106
2025-11-05
Reason
Wells Fargo
Derek Archila
Price Target
$123 -> $106
2025-11-05
downgrade
Overweight
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Soleno Therapeutics to $106 from $123 and keeps an Overweight rating on the shares. The firm says that while this is not the quarter it hoped for exactly, Wells still thinks Vykat XR will be a $1B-plus drug in Prader-Willi syndrome. The firm expects shares to be volatile through year-end 2025 on competitor data but sees the opportunity for shares to outperform on Q4 revenues amid low expectations.
Wells Fargo
Overweight
maintain
$123
2025-09-24
Reason
Wells Fargo
Price Target
$123
2025-09-24
maintain
Overweight
Reason
Wells Fargo believes Acadia Pharmaceuticals' (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics' (SLNO) VYKAT XR. Wells thinks Soleno's shares should trade up at least 20% on Acadia Pharmaceuticals' failure in PWS, Prader-Willi syndrome. The firm remains bullish on VYKAT's launch and would be a buyer at these levels into Q3 print. Wells has an Overweight rating on Soleno with a price target of $123 on the shares.
Wells Fargo
Overweight
initiated
$123
2025-08-20
Reason
Wells Fargo
Price Target
$123
2025-08-20
initiated
Overweight
Reason
Wells Fargo initiated coverage of Soleno Therapeutics with an Overweight rating and $123 price target. The shares are down 23% this month on concerns over Vykat's satiety, competition and and its recent financing which could be a sign of no near-term takeover, the analyst tells investors in a research note. Wells views the concerns as overblown. Vykat's launch in Prader-Willi syndrome remains early, and the significant unmet should drive meaningful near-term uptake, the analyst tells investors in a research note. Wells recommends buying Soleno shares on the recent pullback.
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
